Pneumonic Plague (Yersinia pestis)

Overview


Plain-Language Overview

Pneumonic plague is a serious lung infection caused by the bacterium Yersinia pestis. It primarily affects the respiratory system, leading to severe inflammation and fluid buildup in the lungs. This infection spreads through inhaling droplets from an infected person or animal, making it highly contagious. Symptoms include high fever, cough with bloody sputum, and difficulty breathing. Without prompt treatment, it can rapidly worsen and become life-threatening. The disease is rare but requires urgent medical attention due to its aggressive nature and potential to spread quickly.

Clinical Definition

Pneumonic plague is a fulminant form of plague caused by inhalation of aerosolized Yersinia pestis, a gram-negative bacillus. It represents a primary infection of the lungs or secondary spread from bubonic or septicemic plague. The core pathology involves intense pulmonary inflammation, alveolar edema, and hemorrhage leading to respiratory failure. It is highly contagious via respiratory droplets, posing significant public health risks. Clinically, it presents with sudden onset of fever, productive cough with hemoptysis, and rapidly progressing pneumonia. Without early antibiotic therapy, mortality approaches 100%. Diagnosis and containment are critical due to its potential for outbreaks and bioterrorism use.

Inciting Event

  • Inhalation of respiratory droplets containing Yersinia pestis from a person or animal with pneumonic plague initiates infection.

  • Bite from infected fleas followed by hematogenous spread to lungs can rarely cause secondary pneumonic plague.

  • Exposure to aerosolized bacteria during laboratory accidents or bioterrorism events can trigger disease.

Latency Period

  • Symptoms typically develop within 1 to 4 days after inhalation of Yersinia pestis.

  • The incubation period is usually shorter than bubonic plague due to direct lung infection.

  • Rapid progression to severe pneumonia and respiratory failure can occur within days of symptom onset.

Diagnostic Delay

  • Early symptoms mimic common respiratory infections leading to misdiagnosis as community-acquired pneumonia.

  • Lack of awareness in non-endemic areas causes delayed consideration of plague in differential diagnosis.

  • Rapid progression and nonspecific initial symptoms often result in late presentation to healthcare.

  • Limited availability of specialized laboratory testing for Yersinia pestis delays confirmation.

Clinical Presentation


Signs & Symptoms

  • Sudden onset of high fever and chills

  • Severe productive cough often with bloody or purulent sputum

  • Dyspnea and chest pain due to lung involvement

  • Hemoptysis indicating alveolar hemorrhage

  • Rapid progression to respiratory failure without prompt treatment

History of Present Illness

  • Abrupt onset of high fever, chills, and malaise within days of exposure.

  • Rapid development of productive cough with bloody sputum and pleuritic chest pain.

  • Progressive dyspnea and respiratory distress often leading to hypoxia and cyanosis.

  • Systemic symptoms including severe headache, myalgias, and prostration.

  • Possible progression to septic shock and multi-organ failure if untreated.

Past Medical History

  • History of exposure to rodents, fleas, or endemic areas increases suspicion for pneumonic plague.

  • Previous immunosuppressive conditions or therapies may worsen disease severity.

  • Lack of prior antibiotic prophylaxis or treatment for plague exposure is relevant.

Family History

  • No known heritable predisposition to pneumonic plague exists as it is an infectious disease.

  • Clusters of cases may occur in families due to shared environmental exposures.

  • Family members with similar exposure history may present with related infections.

Physical Exam Findings

  • Tachypnea and respiratory distress with use of accessory muscles

  • Crackles and rales on lung auscultation indicating alveolar involvement

  • Cyanosis due to severe hypoxemia in advanced cases

  • Fever and tachycardia reflecting systemic infection

  • Hypotension in cases progressing to septic shock

Diagnostic Workup


Diagnostic Criteria

Diagnosis of pneumonic plague relies on clinical suspicion in the context of epidemiologic exposure and characteristic symptoms such as fever, hemoptysis, and severe pneumonia. Confirmation requires isolation of Yersinia pestis from respiratory secretions or blood cultures. Rapid diagnostic tests include direct fluorescent antibody staining and polymerase chain reaction (PCR) assays targeting Y. pestis DNA. Chest imaging typically shows bilateral infiltrates consistent with pneumonia. Early identification is essential for prompt treatment and infection control.

Pathophysiology


Key Mechanisms

  • Inhalation of aerosolized Yersinia pestis leads to rapid bacterial proliferation in the lungs causing severe necrotizing pneumonia.

  • Endotoxin release from Yersinia pestis triggers a massive inflammatory cytokine storm resulting in acute respiratory distress syndrome (ARDS).

  • Bacterial evasion of phagocytosis via the F1 capsule and type III secretion system allows unchecked infection and tissue destruction.

  • Sepsis and disseminated intravascular coagulation (DIC) develop due to systemic spread of bacteria and endotoxins.

  • Alveolar hemorrhage and edema result from vascular injury and increased permeability in pulmonary capillaries.

InvolvementDetails
Organs

Lungs are the main organ affected in pneumonic plague, with rapid development of hemorrhagic pneumonia.

Lymph nodes become swollen and necrotic in bubonic plague but may be involved early in pneumonic plague dissemination.

Tissues

Alveolar tissue is the primary site of infection and inflammation leading to pneumonia and respiratory failure.

Lymphatic tissue is involved in early bacterial dissemination and lymphadenitis in plague.

Cells

Macrophages phagocytose Yersinia pestis but the bacteria evade killing by inhibiting phagosome maturation.

Neutrophils are recruited to the lungs and contribute to inflammation and tissue damage in pneumonic plague.

Dendritic cells present bacterial antigens and initiate adaptive immune responses.

Chemical Mediators

Tumor necrosis factor-alpha (TNF-α) mediates systemic inflammation and contributes to septic shock.

Interleukin-1 beta (IL-1β) promotes fever and leukocyte recruitment in infected lung tissue.

Yersinia outer proteins (Yops) are bacterial virulence factors that inhibit host immune signaling and phagocytosis.

Treatments


Pharmacological Treatments

  • Streptomycin

    • Mechanism:
      • Inhibits bacterial protein synthesis by binding the 30S ribosomal subunit.

    • Side effects:
      • Ototoxicity

      • Nephrotoxicity

      • Neuromuscular blockade

    • Clinical role:
      • First-line

  • Gentamicin

    • Mechanism:
      • Binds the 30S ribosomal subunit to inhibit bacterial protein synthesis.

    • Side effects:
      • Nephrotoxicity

      • Ototoxicity

      • Neuromuscular blockade

    • Clinical role:
      • First-line

  • Doxycycline

    • Mechanism:
      • Binds the 30S ribosomal subunit to block bacterial protein synthesis.

    • Side effects:
      • Photosensitivity

      • Gastrointestinal upset

      • Tooth discoloration in children

    • Clinical role:
      • Alternative first-line

  • Ciprofloxacin

    • Mechanism:
      • Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication.

    • Side effects:
      • Tendonitis

      • Gastrointestinal upset

      • QT prolongation

    • Clinical role:
      • Alternative first-line

Non-pharmacological Treatments

  • Provide supportive care including oxygen therapy and mechanical ventilation if respiratory failure occurs.

  • Implement strict isolation precautions to prevent airborne transmission.

  • Ensure adequate hydration and hemodynamic support in septic shock.

Prevention


Pharmacological Prevention

  • Post-exposure prophylaxis with doxycycline or ciprofloxacin for close contacts

  • Pre-exposure prophylaxis with tetracyclines in high-risk populations during outbreaks

  • No widely available vaccine; investigational vaccines exist but are not standard

  • Prompt antibiotic treatment of suspected cases to prevent spread

  • Avoidance of aminoglycosides as monotherapy due to resistance concerns

Non-pharmacological Prevention

  • Rodent and flea control to reduce natural reservoirs of Yersinia pestis

  • Use of personal protective equipment (PPE) when caring for infected patients

  • Isolation of infected individuals to prevent respiratory droplet transmission

  • Avoidance of exposure to endemic areas during outbreaks

  • Public health surveillance and rapid case identification to contain spread

Outcome & Complications


Complications

  • Acute respiratory distress syndrome (ARDS) from severe lung inflammation

  • Septic shock due to systemic dissemination of Yersinia pestis

  • Multi-organ failure including renal and hepatic dysfunction

  • Secondary bacterial pneumonia from superinfection

  • Death if untreated or treatment is delayed

Short-term Sequelae Long-term Sequelae
  • Persistent hypoxemia requiring mechanical ventilation

  • Prolonged fever and systemic inflammatory response

  • Pulmonary abscess formation in some cases

  • Pleural effusions complicating respiratory status

  • Secondary infections due to immune compromise

  • Chronic pulmonary fibrosis following severe lung injury

  • Reduced pulmonary function with restrictive or obstructive patterns

  • Bronchiectasis from recurrent infections or lung damage

  • Psychological sequelae such as post-traumatic stress disorder after critical illness

  • No known direct chronic carrier state for Yersinia pestis

Differential Diagnoses


Pneumonic Plague (Yersinia pestis) versus Bacterial Pneumonia (e.g., Streptococcus pneumoniae)

Pneumonic Plague (Yersinia pestis)

Bacterial Pneumonia (e.g., Streptococcus pneumoniae)

Gram-negative bipolar-staining coccobacillus

Gram-positive diplococci commonly isolated

Exposure to rodents or flea bites common

No specific exposure to rodents or fleas

Rapid progression to severe respiratory distress within 1-4 days

Gradual onset of symptoms over days

Positive culture or PCR for Yersinia pestis

Positive sputum culture for typical respiratory flora

Pneumonic Plague (Yersinia pestis) versus Viral Pneumonia (e.g., Influenza virus)

Pneumonic Plague (Yersinia pestis)

Viral Pneumonia (e.g., Influenza virus)

Gram-negative bacterium detected by culture or PCR

RNA virus detected by PCR

Rapid onset with high fever and hemoptysis

Symptoms develop over several days with fever and cough

Requires prompt antibiotic therapy targeting Yersinia pestis

Improvement with antiviral agents

Pneumonic Plague (Yersinia pestis) versus Pulmonary Tuberculosis

Pneumonic Plague (Yersinia pestis)

Pulmonary Tuberculosis

Bipolar-staining Gram-negative coccobacillus

Acid-fast bacilli on sputum smear

Acute, fulminant respiratory illness

Chronic symptoms over weeks to months

Bilateral patchy infiltrates with rapid progression

Upper lobe cavitary lesions on chest X-ray

Pneumonic Plague (Yersinia pestis) versus Legionnaires' Disease

Pneumonic Plague (Yersinia pestis)

Legionnaires' Disease

Exposure to rodents or flea bites

Exposure to contaminated water sources or air conditioning systems

Positive culture or PCR for Yersinia pestis

Positive urinary antigen test for Legionella pneumophila

Rapid onset with hemoptysis and severe respiratory distress

Subacute onset with high fever and nonproductive cough

Pneumonic Plague (Yersinia pestis) versus Tularemia (Francisella tularensis)

Pneumonic Plague (Yersinia pestis)

Tularemia (Francisella tularensis)

Exposure to rodents or flea bites

Exposure to rabbits, ticks, or deer flies

Bipolar-staining Gram-negative coccobacillus

Small Gram-negative coccobacillus requiring special culture media

Primary severe pneumonia with hemoptysis

Ulceroglandular form common with localized lymphadenopathy

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.